Scientific opinion on the substantiation of health claims related to maize oil and maintenance of normal blood LDL-cholesterol concentrations (ID 3086) pursuant to article 13(1) of regulation (EC) No 1924/2006 by C.V. Agostoni et al.
  EFSA Journal 2011;9(4):2064 
 
Suggested citation: EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the 
substantiation of health claims related to maize oil and maintenance of normal blood LDL-cholesterol concentrations 
(ID 3086) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2064. [14 pp.]. 
doi:10.2903/j.efsa.2011.2064. Available online: www.efsa.europa.eu/efsajournal 
 
© European Food Safety Authority, 2011 
SCIENTIFIC OPINION 
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European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to maize oil and maintenance of normal blood LDL-cholesterol concentrations. The 
scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The food that is the subject of the health claim is maize oil. The Panel considers that maize oil is 
sufficiently characterised in relation to the claimed effect. 
The claimed effect is “corn oil with a guaranteed polyunsaturated fatty acids content (56 % of total 
fatty acids), supplemented with vitamin E”. The target population is assumed to be the general 
population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers 
to maintenance of normal LDL-blood cholesterol concentrations. The Panel considers that 
maintenance of normal blood LDL-cholesterol concentrations is a beneficial physiological effect. 
No studies that investigated whether maize oil had a cholesterol-lowering effect beyond what could be 
expected from the fatty acid composition of maize oil have been provided. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of maize oil and maintenance of normal blood 
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LDL-cholesterol concentrations beyond what could be expected from the fatty acid composition of 
maize oil.  
A claim on the replacement of mixtures of SFAs with cis-MUFAs and/or cis-PUFAs in foods or diets 
and maintenance of normal blood LDL-cholesterol concentrations has already been assessed with a 
favourable outcome. 
A claim on linoleic acid and maintenance of normal blood cholesterol concentrations has also already 
been assessed with a favourable outcome. 
KEY WORDS 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food 
The food that is the subject of the health claim is maize oil. 
Maize oil is a by-product of the milling of maize for the production of starch. The fatty acid 
composition of maize oil consists of about 56 % linoleic acid (LA), 29 % oleic acid and 13 % 
saturated fatty acids (SFAs). 
The Panel considers that the food, maize oil, which is the subject of the health claim, is sufficiently 
characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health (ID 3086) 
The claimed effect is “corn oil with a guaranteed polyunsaturated fatty acids content (56 % of total 
fatty acids), supplemented with vitamin E”. The Panel assumes that the target population is the 
general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to 
maintenance of normal blood LDL-cholesterol concentrations. 
Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the 
normal structure and function of the arteries. 
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
3. Scientific substantiation of the claimed effect (ID 3086) 
None of the references cited in the consolidated list specifically addressed the effects of maize oil on 
blood cholesterol concentrations.  
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 Briefing document for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims: 
http://www.efsa.europa.eu/en/ndameetings/docs/nda100601-ax01.pdf 
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Mensink et al. (2003) found in a meta-analysis of 60 controlled trials that replacing carbohydrates 
with SFAs in an amount representing 1 E% increased LDL-cholesterol concentrations by 
0.032 mmol/L. Replacement with cis-monounsaturated fatty acids (cis-MUFAs) (i.e. oleic acid) 
reduced LDL-cholesterol concentrations by only 0.009 mmol/L. The corresponding reduction in 
LDL-cholesterol concentrations by cis-polyunsaturated fatty acids (cis-PUFAs) was significantly 
larger (i.e. 0.019 mmol/L). 
Wardlaw et al. (1990) compared maize oil and high-oleic acid sunflower oil with butter in a 
randomised cross-over intervention study in 20 healthy men and found that maize oil reduced serum 
total cholesterol concentrations by 21 %, and that high-oleic acid sunflower oil reduced them by 
16 %. In the study by Lichtenstein (1993) rapeseed oil (about 6 % SFAs, 60 % oleic acid, 20 % LA 
and 11 % alpha-linolenic acid), maize oil and olive oil (about 15 % SFAs, 70 % oleic acid and 11 % 
PUFAs (mainly LA)) as part of the National Cholesterol Education Program (NCEP) Step 2 diet were 
compared with the average US diet in a randomised cross-over study in 15 subjects. Both rapeseed oil 
(-12 %) and maize oil (-13 %) reduced serum total cholesterol concentrations significantly more than 
olive oil (-7 %). The Panel notes that the differences observed between oils with respect to their 
effects on blood cholesterol could be explained by their fatty acid composition.  
No studies that investigated whether maize oil has a cholesterol-lowering effect beyond what could be 
expected from the fatty acid composition of maize oil have been provided. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of maize oil and maintenance of normal blood LDL-cholesterol concentrations beyond 
what could be expected from the fatty acid composition of maize oil.  
A claim on the replacement of mixtures of SFAs with cis-MUFAs and/or cis-PUFAs in foods or diets 
and maintenance of normal blood LDL-cholesterol concentrations has already been assessed with a 
favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011). 
A claim on linoleic acid and maintenance of normal blood cholesterol concentrations has also already 
been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies 
(NDA), 2009). 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food, maize oil, which is the subject of the health claim, is sufficiently characterised in 
relation to the claimed effect. 
 The claimed effect is “corn oil with a guaranteed polyunsaturated fatty acids content (56 % of 
total fatty acids), supplemented with vitamin E”. The target population is assumed to be the 
general population. In the context of the proposed wordings, it is assumed that the claimed 
effect refers to maintenance of normal LDL-blood cholesterol concentrations. Maintenance of 
normal blood LDL-cholesterol concentrations is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of maize 
oil and maintenance of normal blood LDL-cholesterol concentrations beyond what could be 
expected from the fatty acid composition of maize oil.  
 A claim on the replacement of mixtures of SFAs with cis-MUFAs and/or cis-PUFAs in foods 
or diets and maintenance of normal blood LDL-cholesterol concentrations has already been 
assessed with a favourable outcome.  
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 A claim on linoleic acid and maintenance of normal blood cholesterol concentrations has also 
already been assessed with a favourable outcome. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-3818). 
The scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation (EC) No 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food, a positive assessment of its safety, nor a decision on whether the food is, or is not, 
classified as foodstuffs. It should be noted that such an assessment is not foreseen in the framework of 
Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to maize oil, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
 
ID Food or Food constituent Health Relationship Proposed wording 
3086 Corn Oil with a guaranteed 
polyunsatured fatty acids 
content (56% of total fatty 
acids), supplemented with 
vitamin E. 
Corn Oil with a 
guaranteed 
polyunsatured fatty 
acids content (56% of 
total fatty acids), 
supplemented with 
vitamin E. 
1- When used within a healthy, 
balanced diet, in combination with 
a healty lifestyle, corn oil with an 
elevated vitamin E content and a 
guaranteed polyunsaturates fatty 
acids content contributes to the 
control of blood cholesterol. 2-
When used within a healthy, 
balanced diet, in combination with 
a healty lifestyle, corn oil 
contributes to the control of blood 
cholesterol. 3-As a part of a healthy 
lifesyle, corn oil helps to maintain 
normal blood cholesterol level.4-As 
a part of a healthy lifesyle, corn oil 
helps to keep blood cholesterol 
levels under control. 
Conditions of use 
- 30 g per day - To be consumed preferably raw 
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GLOSSARY AND ABBREVIATIONS 
LA  Linoleic acid 
LDL  Low-density lipoproteins 
MUFA  Monounsaturated fatty acid 
NCEP  National Cholesterol Education Program 
PUFA  Polyunsaturated fatty acid 
SFA  Saturated fatty acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
